Engagement of sialylated glycans with Siglec receptors on suppressive myeloid cells inhibits anticancer immunity via CCL2.
Sialic acid-binding immunoglobulin-like lectin
myeloid derived suppressor cells
sialoglycans
tumor microenvironment
Journal
Cellular & molecular immunology
ISSN: 2042-0226
Titre abrégé: Cell Mol Immunol
Pays: China
ID NLM: 101242872
Informations de publication
Date de publication:
06 Mar 2024
06 Mar 2024
Historique:
received:
14
08
2023
accepted:
30
01
2024
medline:
7
3
2024
pubmed:
7
3
2024
entrez:
6
3
2024
Statut:
aheadofprint
Résumé
The overexpression of sialic acids on glycans, called hypersialylation, is a common alteration found in cancer cells. Sialylated glycans can enhance immune evasion by interacting with sialic acid-binding immunoglobulin-like lectin (Siglec) receptors on tumor-infiltrating immune cells. Here, we investigated the effect of sialylated glycans and their interaction with Siglec receptors on myeloid-derived suppressor cells (MDSCs). We found that MDSCs derived from the blood of lung cancer patients and tumor-bearing mice strongly express inhibitory Siglec receptors and are highly sialylated. In murine cancer models of emergency myelopoiesis, Siglec-E knockout in myeloid cells resulted in prolonged survival and increased tumor infiltration of activated T cells. Targeting suppressive myeloid cells by blocking Siglec receptors or desialylation strongly reduced their suppressive potential. We further identified CCL2 as a mediator involved in T-cell suppression upon interaction between sialoglycans and Siglec receptors on MDSCs. Our results demonstrated that sialylated glycans inhibit anticancer immunity by modulating CCL2 expression.
Identifiants
pubmed: 38448555
doi: 10.1038/s41423-024-01142-0
pii: 10.1038/s41423-024-01142-0
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (Swiss National Science Foundation)
ID : 310030-184720
Informations de copyright
© 2024. The Author(s).
Références
Kirchhammer N, Trefny MP, Auf der Maur P, Läubli H, Zippelius. A Combination cancer immunotherapies: emerging treatment strategies adapted to the tumor microenvironment. Sci Transl Med. 2022;670:9–14.
Schjoldager KT, Narimatsu Y, Joshi HJ, Clausen H. Global view of human protein glycosylation pathways and functions. Nat Rev Mol Cell Biol. 2020;21:729–49.
Edgar LJ, et al. Sialic acid ligands of CD28 suppress costimulation of T cells. ACS Cent Sci. 2021;7:1508–15.
doi: 10.1021/acscentsci.1c00525
pubmed: 34584952
pmcid: 8461770
Schultz MJ, Swindall AF, Bellis SL. Regulation of the metastatic cell phenotype by sialylated glycans. Cancer Metastasis Rev. 2012;31:501–18.
doi: 10.1007/s10555-012-9359-7
pubmed: 22699311
pmcid: 4079276
MacAuley MS, Crocker PR, Paulson JC. Siglec-mediated regulation of immune cell function in disease. Nat. Rev. Immunol. 2014;14:653–66.
Jandus C, et al. Interactions between Siglec-7/9 receptors and ligands influence NK cell-dependent tumor immunosurveillance. J Clin Investig. 2014;124:1810–20.
doi: 10.1172/JCI65899
pubmed: 24569453
pmcid: 3973073
Wang J, et al. Siglec receptors modulate dendritic cell activation and antigen presentation to T cells in cancer. Front Cell Dev Biol. 2022;10:828916.
Wang J, et al. Siglec-15 as an immune suppressor and potential target for normalization cancer immunotherapy. Nat Med. 2019;25:656–66.
doi: 10.1038/s41591-019-0374-x
pubmed: 30833750
pmcid: 7175920
Ikehara Y, Ikehara SK, Paulson JC. Negative regulation of T cell receptor signaling by Siglec-7 (p70/AIRM) and Siglec-9. J Biol Chem. 2004;279:43117–25.
doi: 10.1074/jbc.M403538200
pubmed: 15292262
Schmassmann P, et al. Targeting the Siglec-sialic acid axis promotes antitumor immune responses in preclinical models of glioblastoma. Sci Transl Med. 2023;15:eadf5302.
doi: 10.1126/scitranslmed.adf5302
pubmed: 37467314
van de Wall S, Santegoets KCM, van Houtum EJH, Büll C, Adema GJ. Sialoglycans and siglecs can shape the tumor immune microenvironment. Trends Immunol. 2020;41:274–85.
Stanczak MA, et al. Targeting cancer glycosylation repolarizes tumor-associated macrophages allowing effective immune checkpoint blockade. Sci Transl Med. 2022;14:eabj1270.
doi: 10.1126/scitranslmed.abj1270
pubmed: 36322632
pmcid: 9812757
Gray MA, et al. Targeted glycan degradation potentiates the anticancer immune response in vivo. Nat Chem Biol. 2020;16:1376–84.
doi: 10.1038/s41589-020-0622-x
pubmed: 32807964
pmcid: 7727925
Barry ST, Gabrilovich DI, Sansom OJ, Campbell AD, Morton JP. Therapeutic targeting of tumour myeloid cells. Nat Rev Cancer. 2023;23:216–37.
doi: 10.1038/s41568-022-00546-2
pubmed: 36747021
Vanhaver C, van der Bruggen P, Bruger AM. Mdsc in mice and men: mechanisms of immunosuppression in cancer. J Clin Med. 2021;10.
Cassetta L, et al. Deciphering myeloid-derived suppressor cells: isolation and markers in humans, mice and non-human primates. Cancer Immunol Immunother. 2019;68:687–97.
doi: 10.1007/s00262-019-02302-2
pubmed: 30684003
pmcid: 6447515
Santegoets KCM, et al. Expression profiling of immune inhibitory Siglecs and their ligands in patients with glioma. Cancer Immunol Immunother. 2019;68:937–49.
doi: 10.1007/s00262-019-02332-w
pubmed: 30953118
pmcid: 6529385
Bronte V, et al. Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards. Nat Commun. 2016.
Siew JJ, Chern Y, Khoo KH, Angata T. Roles of Siglecs in neurodegenerative diseases. Mol Aspects Med. 2022.
Läubli H, Varki A. Sialic acid–binding immunoglobulin-like lectins (Siglecs) detect self-associated molecular patterns to regulate immune responses. Cell Mol Life Sci. 2020;77:593–605.
van Houtum EJH, Büll C, Cornelissen LAM, Adema GJ. Siglec signaling in the tumor microenvironment. Front Immunol. 2021;12.
Adams OJ, Stanczak MA, Von Gunten S, Läubli H. Targeting sialic acid-Siglec interactions to reverse immune suppression in cancer. Glycobiology. 2018;28:640–47.
Youn J-I, Nagaraj S, Collazo M, Gabrilovich DI, Lee, H. Subsets of myeloid-derived suppressor cells in tumor-bearing mice. 2008;1:5791–802.
Hinderlich S, Weidemann W, Yardeni T, Horstkorte R, Huizing M. UDP-GlcNAc 2-epimerase/ManNAc kinase (GNE): a master regulator of sialic acid synthesis. Top Curr Chem. 2015;366:97–138.
doi: 10.1007/128_2013_464
pubmed: 23842869
pmcid: 4161665
Stanczak MA, et al. Self-associated molecular patterns mediate cancer immune evasion by engaging Siglecs on T cells. J Clin Investig. 2018;128:4912–23.
doi: 10.1172/JCI120612
pubmed: 30130255
pmcid: 6205408
Lechner MG, et al. Functional characterization of human Cd33+ And Cd11b+ myeloid-derived suppressor cell subsets induced from peripheral blood mononuclear cells co-cultured with a diverse set of human tumor cell lines. J Transl Med. 2011;9:90.
doi: 10.1186/1479-5876-9-90
pubmed: 21658270
pmcid: 3128058
Alshetaiwi, H et al. Defining the emergence of myeloid-derived suppressor cells in breast cancer using single-cell transcriptomics. Sci. Immunol. 2020;5.
Veglia F, Sanseviero E, Gabrilovich DI. Myeloid-derived suppressor cells in the era of increasing myeloid cell diversity. Nat Rev Immunol. 2021;21:485–98.
Stuart T, et al. Comprehensive integration of single-cell data. Cell. 2019;177:1888–902.e21.
doi: 10.1016/j.cell.2019.05.031
pubmed: 31178118
pmcid: 6687398
Yang Y, Li C, Liu T, Dai X, Bazhin AV. Myeloid-derived suppressor cells in tumors: from mechanisms to antigen specificity and microenvironmental regulation. Front Immunol. 2020;11.
Gschwandtner M, Derler R, Midwood KS. More than just attractive: how CCL2 influences myeloid cell behavior beyond chemotaxis. Front Immunol. 2019;10.
Chun E, et al. CCL2 promotes colorectal carcinogenesis by enhancing polymorphonuclear myeloid-derived suppressor cell population and function. Cell Rep. 2015;12:244–57.
doi: 10.1016/j.celrep.2015.06.024
pubmed: 26146082
pmcid: 4620029
Wang Y, Zhang X, Yang L, Xue J, Hu G. Blockade of CCL2 enhances immunotherapeutic effect of anti-PD1 in lung cancer. J Bone Oncol. 2018;11:27–32.
doi: 10.1016/j.jbo.2018.01.002
pubmed: 29892522
pmcid: 5993943
Lee S, et al. Tumor-associated macrophages secrete CCL2 and induce the invasive phenotype of human breast epithelial cells through upregulation of ERO1-α and MMP-9. Cancer Lett. 2018;437:25–34.
doi: 10.1016/j.canlet.2018.08.025
pubmed: 30165193
Ibarlucea-Benitez I, Weitzenfeld P, Smith P, Ravetch JV. Siglecs-7/9 function as inhibitory immune checkpoints in vivo and can be targeted to enhance therapeutic antitumor immunity. PNAS. 2021;118:e2107424118.
doi: 10.1073/pnas.2107424118
pubmed: 34155121
pmcid: 8256000
Beatson R, et al. The mucin MUC1 modulates the tumor immunological microenvironment through engagement of the lectin Siglec-9. Nat Immunol. 2016;17:1273–81.
doi: 10.1038/ni.3552
pubmed: 27595232
pmcid: 5257269
Barkal AA, et al. CD24 signalling through macrophage Siglec-10 is a target for cancer immunotherapy. Nature. 2019;572:392–6.
doi: 10.1038/s41586-019-1456-0
pubmed: 31367043
pmcid: 6697206
Crocker PR, Paulson JC, Varki A. Siglecs and their roles in the immune system. Nat Rev Immunol. 2007;7:255–66.
Luke JJ, et al. Abstract CT034: GLIMMER-01: initial results from a phase 1 dose escalation trial of a first-in-class bi-sialidase (E-602) in solid tumors. Cancer Res. 2023;83:CT034–CT034.
doi: 10.1158/1538-7445.AM2023-CT034
Jenner J, Kerst G, Handgretinger R, Müller I. Increased α2,6-sialylation of surface proteins on tolerogenic, immature dendritic cells and regulatory T cells. Exp Hematol. 2006;34:1211–17.
doi: 10.1016/j.exphem.2006.04.016
Chen X, et al. Induction of myelodysplasia by myeloid-derived suppressor cells. J Clin Investig. 2013;123:4595–611.
doi: 10.1172/JCI67580
pubmed: 24216507
pmcid: 3809779
Mariño KV, Cagnoni AJ, Croci DO, Rabinovich GA. Targeting galectin-driven regulatory circuits in cancer and fibrosis. Nat Rev Drug Discov. 2023.
Tcyganov E, Mastio J, Chen E, Gabrilovich DI. Plasticity of myeloid-derived suppressor cells in cancer. Curr Opin Immunol. 2018;51:76–82.
Veglia F, et al. Analysis of classical neutrophils and polymorphonuclear myeloid-derived suppressor cells in cancer patients and tumor-bearing mice. J Exp Med. 2021;218:e20201803.
doi: 10.1084/jem.20201803
pubmed: 33566112
pmcid: 7879582
Clausen BE, Burkhardt C, Reith W, Renkawitz R, Förster I. Conditional gene targeting in macrophages and granulocytes using LysMcre mice. Transgenic Res. 1999;8:265–77.
doi: 10.1023/A:1008942828960
pubmed: 10621974
Huang X, Huang Y. Cellsnp-lite: an efficient tool for genotyping single cells. Bioinformatics. 2021;37:4569–71.
doi: 10.1093/bioinformatics/btab358
pubmed: 33963851
Huang Y, McCarthy DJ, Stegle O. Vireo: Bayesian demultiplexing of pooled single-cell RNA-seq data without genotype reference. Genome Biol. 2019;20:273.
doi: 10.1186/s13059-019-1865-2
pubmed: 31836005
pmcid: 6909514
Wu T, et al. clusterProfiler 4.0: a universal enrichment tool for interpreting omics data. Innovation. 2021;2:100141.
pubmed: 34557778
pmcid: 8454663
Lin CW, et al. Terminal disialylated multiantennary complex-type N-glycans carried on acutobin define the glycosylation characteristics of the Deinagkistrodon acutus venom. Glycobiology. 2011;21:530–42.
doi: 10.1093/glycob/cwq195
pubmed: 21106559
Dell A, et al. Mass spectrometry of carbohydrate-containing biopolymers. Guide Tech Glycobiol. 1994;230:108–32.
doi: 10.1016/0076-6879(94)30010-0
Ceroni A, et al. GlycoWorkbench: a tool for the computer-assisted annotation of mass spectra of glycans. J Proteome Res. 2008;7:1650–59.
doi: 10.1021/pr7008252
pubmed: 18311910